-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2026-04-29
GenSci’s NK3R Antagonist for VMS Phase II Study Results Published in MenopauseLearn More
-
2026-04-27
GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026Learn More
-
2026-03-17
Positive Phase II Results for GenSci's Firsekibart in Pediatric Rare Disease PublishedLearn More
-
2026-03-11
GenSci128, an Investigational Cancer Therapy from Gensci Pharmaceuticals, Receives FDA Orphan Drug Designation for Pancreatic CancerLearn More
-
2026-02-14
GenSci136, an APRIL/BAFF Dual Antagonist, Granted Clinical Trial Approval for IgANLearn More
-
2026-01-16
GenSci Unveils Seven Innovative Pipeline at JPM 2026Learn More